Managing maternal glucose during gestation remains one of the most demanding tasks in modern reproductive medicine. Achieving strict glycaemic targets is critical because maternal fluctuations directly impact fetal development, organogenesis, and long-term metabolic health. While subcutaneous insulin therapy serves as the undisputed cornerstone of treatment, many patients experience significant glycaemic variability, postprandial excursions, and escalating insulin resistance as gestation advances. Consequently, clinicians are actively exploring novel strategies, including adjunctive metformin in pregnancy for individuals living with type 1 diabetes mellitus (T1DM). Emerging clinical evidence from multicentre observational cohorts suggests that adding an oral insulin sensitiser may help stabilise blood glucose profiles. Real-world insights and continuous glucose monitoring (CGM) metrics are shedding new light on this clinical paradigm.

Understanding the Clinical Dilemma in T1D Pregnancies

Pregnancy naturally induces progressive insulin resistance, particularly during the late second and third trimesters. In individuals with T1DM, placental hormones exacerbate metabolic instability and sharply elevate daily insulin requirements. To prevent fetal macrosomia, neonatal hypoglycaemia, and maternal preeclampsia, international consensus guidelines mandate stringent glucose targets. Clinicians typically aim for fasting levels below 95 mg/dL and one-hour postprandial levels under 140 mg/dL.

However, escalating insulin doses frequently leads to undesirable clinical trade-offs. Higher exogenous insulin administration increases maternal adiposity, promotes excessive gestational weight gain, and heightens the risk of severe nocturnal hypoglycaemia. Furthermore, sharp swings between hyper- and hypoglycaemia degrade maternal quality of life and place immense emotional distress on expectant mothers. Traditional self-monitoring via capillary finger-pricks often fails to detect rapid postprandial spikes or silent overnight nadirs. Therefore, maternal-fetal medicine specialists require therapeutic approaches that optimize glycaemic stability without disproportionately escalating hypoglycaemic episodes. The search for adjunctive agents that can mitigate insulin resistance and smooth glucose variability has therefore gained significant momentum.

Role of Adjunctive Metformin in Pregnancy and Glycaemic Metrics

Metformin acts primarily as a biguanide by suppressing hepatic gluconeogenesis and enhancing peripheral insulin sensitivity in skeletal muscle. Although clinicians widely prescribe metformin for gestational diabetes and type 2 diabetes, its off-label use in T1DM pregnancy has remained controversial. A recent multicentre Australian cohort study evaluated the addition of metformin to standard insulin regimens in pregnant women with T1DM. The study revealed promising findings, notably showing that adjunctive therapy improved overall glycaemic control.

Importantly, the addition of metformin allowed clinicians to moderate the rapid escalation of daily insulin doses that typically occurs across gestation. By improving tissue sensitivity to exogenous insulin, the agent facilitated smoother postprandial glucose transitions. Patients receiving combination therapy exhibited fewer sharp postprandial glucose surges compared to baseline values. In addition, the therapy helped attenuate excessive maternal gestational weight gain, which represents an independent risk factor for hypertensive disorders of pregnancy. Consequently, these findings encourage clinicians to re-evaluate biguanides as complementary tools in selected individuals experiencing severe insulin resistance during pregnancy.

Continuous Glucose Monitoring Insights and Time in Range

The integration of continuous glucose monitoring (CGM) has fundamentally revolutionized obstetric diabetes management. Unlike glycated hemoglobin (HbA1c), which provides only a static three-month retrospective average, CGM captures dynamic, real-time glucose trajectories. Standard pregnancy-specific consensus guidelines recommend that women with T1DM achieve a Time in Range (TIR, 63–140 mg/dL) of greater than 70%, while limiting Time Below Range (TBR, <63 mg/dL) to less than 4%.

The Australian cohort represents the first reported investigation evaluating adjunctive metformin in pregnant women with T1DM using standardized CGM metrics. Researchers observed a demonstrable increase in TIR following the introduction of metformin. Furthermore, the data showed a significant reduction in overall glycaemic variability, as measured by standard deviation and coefficient of variation. By blunting glucose excursions, the therapy helped patients spend more hours within the tight physiological target window. Remarkably, this improvement in TIR occurred without any concomitant rise in severe maternal hypoglycaemia. These granular CGM profiles provide robust objective validation that adjunct therapy enhances real-time metabolic stability during pregnancy.

Evaluating Maternal, Fetal, and Neonatal Safety

Safety considerations remain paramount whenever clinicians evaluate pharmacological interventions during gestation. Metformin readily crosses the human placenta, exposing the developing fetus to circulating drug concentrations similar to maternal levels. Historically, large clinical trials in type 2 diabetes and gestational diabetes, such as the MiTy and MiG trials, demonstrated maternal benefits alongside reassuring neonatal outcomes. However, investigators noted specific signals, including slightly lower birth weights and potential shifts in long-term offspring adiposity.

In the T1DM cohort, preliminary findings indicated favorable maternal outcomes without significant adverse perinatal events. The reduction in maternal glucose variability directly correlated with lower risks of fetal overgrowth, large-for-gestational-age infants, and operative deliveries. Nevertheless, clinicians must maintain careful vigilance regarding potential neonatal impacts. Metformin does not replace insulin in T1DM, and improper titration could theoretically increase the risk of ketosis if insulin doses decrease excessively. Therefore, obstetricians and endocrinologists must rigorously assess fetal growth parameters via serial ultrasonography. Multidisciplinary teams must balance the immediate maternal glycaemic advantages against long-term developmental considerations.

Translating Evidence to Obstetric and Endocrine Practice in India

The clinical implications of these findings hold substantial relevance for healthcare providers across India. South Asian women exhibit higher baseline insulin resistance and face a distinct metabolic phenotype with elevated risks of pregnancy-related complications. In India, managing T1DM during pregnancy presents formidable hurdles, including variable access to specialized diabetes educators, socioeconomic diversity, and cultural dietary habits rich in refined carbohydrates.

Indian obstetricians and physicians frequently encounter pregnant women who struggle to attain tight glycaemic targets despite intensive multiple daily injection (MDI) regimens. In such high-risk scenarios, carefully selected adjunctive metformin therapy could potentially reduce daily insulin costs and mitigate excessive weight gain. However, healthcare teams must deploy continuous glucose monitoring or structured self-monitoring before initiating such adjuncts. Clinicians must thoroughly counsel patients regarding the off-label nature of this approach, emphasizing that insulin remains the essential life-saving therapy. Structured antenatal care, regular ketone screening, and collaborative decision-making between endocrinologists and obstetricians remain essential to ensure optimal maternal and neonatal wellbeing in Indian clinical settings.

Future Directions and Research Horizons

While real-world case series provide compelling preliminary evidence, substantial evidence gaps persist. Large-scale, randomized controlled trials are urgently needed to establish definitive safety and efficacy benchmarks for adjunctive metformin in T1DM pregnancies. Future studies must evaluate longitudinal neonatal outcomes, including childhood growth kinetics, neurodevelopmental markers, and metabolic health. Furthermore, researchers should explore how adjunctive pharmacotherapy interacts with advanced automated insulin delivery (AID) and closed-loop hybrid systems. As reproductive medicine embraces personalised metabolic care, targeted therapies may soon provide pregnant women with safer, more resilient glycaemic pathways.

Frequently Asked Questions (FAQs)

Can metformin replace insulin in pregnant women with type 1 diabetes?

No, metformin cannot replace insulin in type 1 diabetes mellitus under any circumstances. Individuals with type 1 diabetes lack endogenous pancreatic insulin production and depend on exogenous insulin for survival. Metformin functions purely as an adjunctive insulin sensitiser. It helps reduce peripheral resistance and smooths postprandial glucose swings. Healthcare providers must continue basal-bolus insulin regimens alongside any adjunctive therapy to prevent diabetic ketoacidosis and sustain maternal and fetal health.

How does continuous glucose monitoring improve pregnancy management in T1D?

Continuous glucose monitoring delivers real-time interstitial glucose data, enabling immediate therapeutic adjustments. Standard pregnancy metrics aim for a Time in Range of 63 to 140 mg/dL greater than 70%. CGM captures silent nocturnal hypoglycaemia and postprandial spikes that traditional finger-prick tests frequently miss. By visualizing glucose trends and calculating glycaemic variability, clinicians and patients can optimize insulin titration, adjust dietary inputs, and achieve safer, tighter glycaemic control throughout each trimester.

Does metformin use during pregnancy harm fetal growth or development?

Current clinical evidence indicates that metformin does not increase the risk of major congenital malformations when used during pregnancy. Because metformin crosses the placenta, researchers have observed lower maternal gestational weight gain and reduced rates of fetal macrosomia. However, some long-term studies report subtle differences in childhood subcutaneous fat distribution. Clinicians recommend careful ultrasound monitoring of fetal growth kinetics whenever prescribing metformin as an adjunct during gestation.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when interpreting and applying this information. Clinical management must follow individualized patient assessments and adhere to relevant institutional protocols and applicable local regulations. Refer to the latest local and national guidelines for clinical practice.

References

1. Govinna M et al. Adjunctive metformin therapy in type 1 diabetes in pregnancy: insights from an Australian cohort. Intern Med J. 2026 Aug 16. doi: 10.1111/imj.70607. PMID: 42604858.
2. American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S282-S298.
3. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347-2359.
4. Feig DS, Murphy HR, Asztalos EV, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834-844.